Mark McCamish
Director/Board Member presso AVADEL PHARMACEUTICALS PLC
Patrimonio netto: 1 M $ in data 31/03/2024
Posizioni attive di Mark McCamish
Società | Posizione | Inizio | Fine |
---|---|---|---|
AVADEL PHARMACEUTICALS PLC | Director/Board Member | 05/12/2019 | - |
Independent Dir/Board Member | 05/12/2019 | - | |
RAFAEL HOLDINGS, INC. | Director/Board Member | 14/06/2021 | - |
Independent Dir/Board Member | 14/06/2021 | - | |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Director/Board Member | - | - |
Chief Executive Officer | 01/11/2020 | - | |
President | 01/11/2020 | - |
Storia della carriera di Mark McCamish
Precedenti posizioni note di Mark McCamish
Società | Posizione | Inizio | Fine |
---|---|---|---|
VINCERX PHARMA, INC. | Director/Board Member | 23/12/2020 | 13/05/2021 |
Independent Dir/Board Member | 23/12/2020 | 13/05/2021 | |
FORTY SEVEN, INC. | Director/Board Member | 01/05/2017 | 07/04/2020 |
Chief Executive Officer | 01/05/2017 | 07/04/2020 | |
President | 01/05/2017 | 07/04/2020 | |
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | 01/07/2009 | 01/04/2017 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Chief Tech/Sci/R&D Officer | 01/12/2008 | 01/04/2009 |
PDL BIOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 21/02/2007 | 01/12/2008 |
Perlegen Sciences, Inc.
Perlegen Sciences, Inc. Drugstore ChainsRetail Trade Perlegen Sciences, Inc. discovers and develops drugs. Its product pipeline consists of targeted drug candidates addressing type II diabetes and dyslipidemia markets. The company's products include PGX-510 and PGX-520. It operates in the United States, European Union, and Japan. Perlegen Sciences was co-founded by Brad A. Margus, David R. Cox, and Stephen P. A. Fodor in 2000 and is headquartered in Mountain View, CA | Chief Tech/Sci/R&D Officer | 01/01/2003 | 01/02/2007 |
░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░ ░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░░ ░░ ░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formazione di Mark McCamish
The Pennsylvania State University | Doctorate Degree |
University of California, Santa Barbara | Graduate Degree |
David Geffen School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 15 |
Irlanda | 2 |
Posizioni
Director/Board Member | 6 |
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 3 |
Settori
Health Technology | 9 |
Consumer Services | 6 |
Retail Trade | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 4 |
---|---|
ABBOTT LABORATORIES | Health Technology |
AVADEL PHARMACEUTICALS PLC | Health Technology |
RAFAEL HOLDINGS, INC. | Finance |
VINCERX PHARMA, INC. | Health Technology |
Aziende private | 6 |
---|---|
Perlegen Sciences, Inc.
Perlegen Sciences, Inc. Drugstore ChainsRetail Trade Perlegen Sciences, Inc. discovers and develops drugs. Its product pipeline consists of targeted drug candidates addressing type II diabetes and dyslipidemia markets. The company's products include PGX-510 and PGX-520. It operates in the United States, European Union, and Japan. Perlegen Sciences was co-founded by Brad A. Margus, David R. Cox, and Stephen P. A. Fodor in 2000 and is headquartered in Mountain View, CA | Retail Trade |
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Health Technology |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
PDL BioPharma, Inc.
PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Forty Seven, Inc.
Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Health Technology |
- Borsa valori
- Insiders
- Mark McCamish
- Esperienza